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Abstract Eukaryotic initiation factor eIF2B mediates a key 
regulatory step in peptide-chain initiation and is acutely activated 
by insulin, although it is not clear how. Inhibitors of 
phosphatidylinositide 3-kinase blocked activation of eIF2B, 
although rapamycin, which inhibits the p70 S6 kinase pathway, 
did not. Furthermore, a dominant negative mutant of PI 3-kinase 
also prevented activation of eIF2B, while a Sos-mutant, which 
blocks MAP kinase activation, did not. The data demonstrate 
that a pathway distinct from MAP and p70 S6 kinases regulates 
eIF2B. Glycogen synthase kinase-3 (GSK-3) phosphorylates and 
inactivates eIF2B. In all cases, eIF2B and GSK-3 were regulated 
reciprocally. Dominant negative PI 3-kinase abolished the 
insulin-induced inhibition of GSK-3. These data strongly support 
the hypothesis that insulin activates eIF2B through a signalling 
pathway involving PI 3-kinase and inhibition of GSK-3. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Protein synthesis is activated at the level of translation by a 
variety of stimuli. Physiologically, one of the most important 
of these is insulin [1] which activates overall protein synthesis 
within a few minutes of its administration. Several control 
points for mammalian translation have been identified and 
these may regulate either overall rates of protein synthesis 
or the translation of specific mRNAs [1-5]. The rapamycin-
sensitive ('FRAP'/mTOR) signalling pathway appears to be 
involved in several of these [6,7]. However, rapamycin only 
slightly represses overall or insulin-stimulated rates of protein 
synthesis, especially in the short term [8,9]. This suggests that 
(a) further, insulin-activated but rapamycin-insensitive path-
way mediates a high proportion of the stimulation of protein 
synthesis seen in response to insulin [8]. 
Eukaryotic initiation factor eIF2B mediates the recycling of 
the protein, eIF2, which binds the initiator Met-tRNA (Met-
tRNA;) to the 40S ribosomal subunit and is required for every 
initiation event. eIF2 binds GTP and the GTP is hydrolysed 
late in the initiation process, yielding the inactive [eIF2.GDP] 
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complex. eIF2B acts on this to promote the release of the 
tightly bound GDP and allow eIF2 to bind GTP. Since 
[eIF2.GTP] is required for each initiation event, this rate-lim-
iting eIF2B-mediated recycling step plays a key role in the 
regulation of mRNA translation [10]. We and others have 
shown that eIF2B is activated by insulin in several cell types 
[11-14], by glucose in pancreatic islets [15] and following mi-
togenic stimulation of T-lymphocytes [16]. 
eIF2B is a substrate for several protein kinases in vitro, 
including casein kinases (CKs)-l and -2 and glycogen synthase 
kinase (GSK)-3 [10,17,18]. Phosphorylation by GSK-3 inhib-
its the activity of eIF2B and reverses the activation reported 
to be brought about by its phosphorylation by CK-1 or CK-2 
[18]. GSK-3 is itself inactivated in response to insulin, by a 
mechanism which involves its phosphorylation at a conserved 
N-terminal Ser residue [19-21]. Data obtained using selective 
inhibitors point to an essential role for phosphatidylinositide 
3-kinase (PI 3-kinase) in the regulation of GSK-3 by insulin 
[22-24], and recent findings suggest that the link between 
them may be provided by protein kinase B (PKB), which 
lies downstream of PI 3-kinase and can phosphorylate 
GSK-3 in vitro at the regulatory site [24]. Recent studies 
have shown that PI 3-kinase plays an essential role in the 
activation of protein synthesis by insulin and that this largely 
involves a signalling mechanism distinct from the rapamycin-
sensitive p70 S6 kinase (mTOR/FRAP) pathway [8]. 
Here we report the results of the first studies addressing the 
signalling pathway through which insulin activates eIF2B. We 
show that the activation of eIF2B by insulin requires PI 3-
kinase but is not mediated by the FRAP/mTOR pathway. 
eIF2B activation is also independent of MAP kinase. These 
data demonstrate that a distinct signalling pathway operates 
to activate eIF2B and are consistent both with (i) a key role 
for GSK-3 in the activation of eIF2B and hence translation 
initiation by insulin and (ii) an absolute requirement for PI 3-
kinase for the activation of protein synthesis by insulin [8]. 
2. Materials and methods 
2.1. Adenovirus vectors and treatment of cells 
The dominant negative PI 3-kinase (Ap85) and a dominant negative 
Sos (ASos) mutants were as described previously [25,26]. Recombinant 
adenovirus vectors (termed pAxCAAp85 or pAxCAASos) were gener-
ated by cloning the corresponding cDNAs into pAxCAwt [27] and 
cotransfection into 293 cells with DNA-TPC, as described previously 
[28]. An adenovirus vector encoding the lacZ gene (pAxCALacZ) [27] 
was a gift from I. Saito, Tokyo University. CHO-IR cells, Chinese 
hamster ovary cells overexpressing human insulin receptor [25], were 
infected with adenovirus vectors at a multiplicity of infection (MOI, 
plaque-forming units/cell) of 10, then the cells were used for experi-
ments 48 h after infection. In some experiments, a similar cell line, 
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CHO.T cells [29], which also overexpress the human insulin receptor, 
were employed. In all cases, cells were grown, treated with insulin and 
extracted as described previously [26,29]. 
2.2. Assays for enzymes and translation factors 
MAP kinase assays were performed after immunoprecipitation with 
anti-MAP kinase antibodies (aC92) using myelin basic protein as 
substrate as described previously [26]. PI 3-kinase activity was assayed 
after immunoprecipitation with anti-phosphotyrosine antibodies 
(PY20; Transduction laboratories) as described previously [25]. 
GSK-3 and eIF2B were routinely assayed as described previously 
[14,17,30,31]. 
3. Results and discussion 
3.1. Insulin activates eIF2B and inactivates GSK-3 in CHO.IR 
cells 
Two similar CHO cell lines, each expressing the human 
insulin receptor, have been used in the various experiments 
reported here. These are termed CHO.T [29] and CHO-IR [25] 
cells. Fig. 1A, shows that insulin treatment of CHO.T cells led 
to the 2-fold activation of eIF2B within 10 min of insulin 
treatment (Fig. 1A). Insulin also resulted in the inactivation 
of GSK-3, in this case to ~ 40% of the activity in control cells 
(Fig. IB) [17]. Essentially identical effects of insulin on eIF2B 
and on GSK-3 were also seen in CHO-IR cells (as described 
below, Sections 3.2 and 3.3). 
The best studied mechanism for the regulation of eIF2B 
activity involves the phosphorylation of its substrate, eIF2, 
on its a-subunit, eIF2(ocP) being a potent competitive inhib-
itor of eIF2B. In these experiments insulin did not affect the 
level of eIF2a phosphorylation as assessed by isoelectric fo-
cusing ( = 15% with or without insulin; data not shown). This 
observation is consistent with other work in muscle 
[11,13,32,33] and in Swiss 3T3 cells [14] showing that insulin 
or diabetes do not affect the state of phosphorylation of 
eIF2a and points to an alternative mechanism regulating 
the activity of eIF2B. 
3.2. Interference with PI 3-kinase prevents the activation of 
eIF2B by insulin 
In CHO cells expressing the insulin receptor, wortmannin, 
an inhibitor of PI 3-kinase, inhibited the effects of insulin on 
the activities of both eIF2B and GSK-3 (Fig. 1A,B). In con-
trast, rapamycin, which blocks the FRAP/mTOR pathway, 
which may also lie downstream of PI 3-kinase [34], was with-
out effect on the activation of eIF2B by insulin (Fig. 1A) and 
also had no effect on the inactivation of GSK-3 caused by this 
hormone (Fig. IB and [22-24]). This is an important control 
given that effects of wortmannin or other treatments which 
affect PI 3-kinase could indicate the involvement of either the 
FRAP/TOR signalling pathway or of GSK-3 (or both). 
Insulin potently activated PI 3-kinase in CHO.IR cells (Fig. 
2A,B). In contrast, in cells infected with adenovirus expressing 
a dominant negative mutant of the p85 subunit of PI 3-kinase 
(Ap85), the activation of this enzyme by insulin was severely 
inhibited (Fig. 2A,B). On the other hand, insulin did activate 
PI 3-kinase in cells infected either with control virus encoding 
|3-galactosidase or virus expressing a dominant interfering mu-
tant of the GTP/GDP exchange factor Sos, which prevents the 
activation of Ras [26] (Fig. 2A,B). As expected, wortmannin 
also blocked the activity of PI 3-kinase (Fig. 2A). The inter-
fering mutant of PI 3-kinase (Ap85) almost completely 
blocked the activation of eIF2B by insulin (Fig. 3A), whereas 
250 
o 
k 
c 
o 
u 
s? 
i? 
> 4-1 
o TO 
CD 
C>l 
LL 
O 
200 
150 
100 
50 
A I 
I l+R l+W 
120 
? 1 0 0 
§ 
O 
ns 
r) ■ 
o 
80 
60 
40 
20 
B 
0 
Fig. 1. Regulation of eIF2B and GSK-3 in Chinese hamster ovary 
cells expressing the insulin receptor. The activities of eIF2B (panel 
A) and GSK-3 (panel B) were measured in extracts from untreated 
CHO cells (C) or cells treated with insulin (I, 20nM) for 10 min in 
the absence or presence of wortmannin (W, lOOnM) or rapamycin 
(R, 20nM), these inhibitors being added 30 min prior to insulin 
treatment of the cells. The data shown are from three separate ex-
periments, assays being performed in duplicate in each case. 
eIF2B was activated normally in cells infected with control 
virus or virus encoding dominant negative Sos. 
The ability of insulin to activate MAP kinase was strongly 
suppressed in cells expressing the Sos mutant (ASos cells, [26]), 
whereas insulin did activate MAP kinase in control cells, and, 
to similar extents, in cells infected with control virus or virus 
expressing the Ap85 mutant (Fig. 2C). Thus, as expected, the 
Ap85 mutant did not interfere with MAP kinase activation, 
but blocked activation of PI 3-kinase, while the ASos muta-
tion blocks MAP kinase activation but not that of PI 3-kin-
ase. The expression of the dominant-negative ASos mutant did 
not interfere with the activation of eIF2B (Fig. 3A), indicating 
that this was independent both of Ras activation [26] and the 
MAP kinase cascade. 
3.3. Regulation of GSK-3 by insulin requires PI 3-kinase 
In CHO.IR cells infected with control virus or with virus 
expressing the ASos mutant, insulin treatment led to the in-
hibition of GSK-3 (Fig. 3B). In contrast, in cells expressing 
the Ap85 mutant, the ability of insulin to inhibit GSK-3 was 
sharply reduced relative to control cells (Fig. 3B). Thus the 
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Fig. 2. Effects of wortmannin or overexpression of dominant negative molecules on PI 3-kinase and MAP kinase in CHO-IR cells. Control or 
virus-infected cells or uninfected cells pre-treated with 100 nM wortmannin for 20 min were incubated in the absence or presence of 0.1 uM in-
sulin for 5 min. Cells were then extracted and samples prepared for assay of Pi 3-kinase or MAP kinase. PI 3-kinase was immunoprecipitated, 
and its activity was assayed (panels A and B) and, separately, MAP kinase was immunoprecipitated and then assayed (panel C). Panel A shows 
the data, in duplicate, from a single typical experiment measuring PI 3-kinase, and is an autoradiograph of a chromatogram corresponding to 
a PI 3-kinase assay: the positions of the origin and of PI 3-phosphate (PI3P) are indicated. Wort, cells pre-treated with wortmannin (lOOnM); 
Ap85, ASos and (3-gal indicate cells infected with the pAxCAAp85, pAxCAASos or pAxCALacZ viruses. Where no virus is indicated, cells were 
non-infected ones. Panel B shows cumulative PI 3-kinase assay data which are mean ± S.E. from at least three independent experiments. In pan-
els B and C (see below), C, untreated cells; I, insulin (0.1 uM insulin for 10 min); W, wortmannin (100 nM); and LacZ, ASos and Ap85 indi-
cate infection with the corresponding viruses. Panel C shows cumulative data for MAP kinase assays. Data are mean ± S.E. from at least three 
experiments and the labelling of the figure is as for panel B. 
M A P kinase pathway does not appear to mediate the regula-
tion of GSK-3 by insulin [24] while PI 3-kinase activity plays 
a key role in its control [22-24]. This corroborates other da ta 
obtained using alternative approaches employing selective 
(but not necessarily uniquely specific) inhibitors of M A P kin-
ase activation or of PI 3-kinase [24]. These findings are at 
variance with the conclusions of Eldar-Finkelman et al. [35] 
who used a transfection-based approach to explore the regu-
lation of GSK-3 by epidermal growth factors and concluded 
that this required the M A P kinase pathway. 
3.4. Concluding remarks 
The da ta described here lend further support to the model 
for the regulation of GSK-3 activity advanced by Cross et al. 
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Fig. 3. PI 3-kinase but not MAP kinase is required for the activa-
tion of eIF2B by insulin. The activities of eIF2B (panel A) and 
GSK-3 (panel B) were determined in extracts of control CHO cells, 
treated with or without insulin, or cells infected with control adeno-
virus (LacZ) or adenovirus encoding Ap85 or ASos interfering mu-
tants (as indicated), treated with insulin (0.1 uM for 10 min). 
[24]. Any of three manipulations designed either to inhibit PI 
3-kinase or block its activation sharply reduced or eliminated 
the ability of insulin to bring about the inactivation of GSK-
3. Similar effects have been reported before for the inhibitors 
[24], but this is the first occasion where interfering mutants of 
PI 3-kinase have been employed. Use of these mutants has 
previously been shown to block the insulin-induced transloca-
tion of glucose transporters and activation of glucose trans-
port [25]. The data obtained here underline the requirement 
for PI 3-kinase for the insulin-induced regulation of GSK-3. 
In particular, this approach avoids the potential problems 
which may be encountered using inhibitors, which may also 
affect other targets in the cell. This is especially relevant in the 
case of wortmannin, which, since the earlier studies were car-
ried out, has been shown to inhibit other enzymes [36-38]. 
The most important new results reported here concern the 
signalling mechanisms through which insulin regulates eIF2B. 
We and others have previously shown that insulin activates 
this key step in translation [13,14,39]. We have also shown 
that eIF2B is a substrate for GSK-3, at least in vitro, and 
phosphorylation of eIF2B causes its inactivation (Welsh and 
Proud, unpublished; see also [18]). The present data show that 
insulin activates eIF2B through a signalling pathway which 
involves PI 3-kinase, but is independent of the FRAP/ 
mTOR pathway (as shown by the lack of inhibition by rapa-
mycin of insulin's effect on eIF2B). The activation of eIF2B is 
also independent of MAP kinase, as demonstrated by the 
absence of an effect of the ASos mutant on the activation of 
eIF2B by insulin. Mendez et al. [8] showed that wortmannin 
caused a profound inhibition of the activation of protein syn-
thesis by insulin and that this was largely independent of the 
FRAP/mTOR pathway. Thus, a major element of the insulin-
induced activation of protein synthesis involves a PI 3-kinase-
dependent but FRAP/mTOR-independent regulatory path-
way. All the available data are consistent with the idea that 
this involves the GSK-3 mediated regulation of eIF2B, whose 
activation would increase the availability of active [eIF2.GTP] 
complexes, which are required for every initiation event. The 
present data fully support the idea that the stimulation of 
eIF2B resulting from the inactivation of GSK-3 by insulin 
plays a major role in the overall activation of translation by 
insulin. Other insulin activated signalling events - e.g. MAP 
kinase and phosphorylation of eIF4E [40], the FRAP/mTOR 
pathway and regulation of S6 phosphorylation [41], 4E-BP1 
[9,42^-4] or eEF2 [6] - are likely to make quantitatively lesser 
contributions to the activation of translation although their 
inputs may be especially important for the regulation of the 
translation of specific mRNAs, e.g. those with structured 5'-
UTRs [9,45] or which possess 5'-terminal polypyrimidine 
tracts [46]. We are grateful to Dr. AJ . Loughlin (Kent) for 
preparing the eIF2 used in this work. 
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